<SEC-DOCUMENT>0001493152-25-003269.txt : 20250122
<SEC-HEADER>0001493152-25-003269.hdr.sgml : 20250122
<ACCEPTANCE-DATETIME>20250122172837
ACCESSION NUMBER:		0001493152-25-003269
CONFORMED SUBMISSION TYPE:	SCHEDULE 13G
PUBLIC DOCUMENT COUNT:		1
FILED AS OF DATE:		20250122

SUBJECT COMPANY:	

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			MANGOCEUTICALS, INC.
		CENTRAL INDEX KEY:			0001938046
		STANDARD INDUSTRIAL CLASSIFICATION:	SERVICES-MISC HEALTH & ALLIED SERVICES, NEC [8090]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				873841292
		STATE OF INCORPORATION:			TX
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		SCHEDULE 13G
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	005-94055
		FILM NUMBER:		25546969

	BUSINESS ADDRESS:	
		STREET 1:		15110 DALLAS PKWY, SUITE 600
		CITY:			DALLAS
		STATE:			TX
		ZIP:			75248
		BUSINESS PHONE:		(833) 626-4679

	MAIL ADDRESS:	
		STREET 1:		15110 DALLAS PKWY, SUITE 600
		CITY:			DALLAS
		STATE:			TX
		ZIP:			75248

FILED BY:		

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			GREENFIELD INVESTMENTS LTD.
		CENTRAL INDEX KEY:			0002052615
		ORGANIZATION NAME:           	
		IRS NUMBER:				000000000

	FILING VALUES:
		FORM TYPE:		SCHEDULE 13G

	BUSINESS ADDRESS:	
		STREET 1:		C/O KARAM & MISSICK, ATTORNEYS
		STREET 2:		203/4 REGENT VILLAGE
		CITY:			PROVIDENCIALES, GRACE BAY
		STATE:			W7
		ZIP:			TKCAZZI
		BUSINESS PHONE:		1-649-941-5082

	MAIL ADDRESS:	
		STREET 1:		C/O KARAM & MISSICK, ATTORNEYS
		STREET 2:		203/4 REGENT VILLAGE
		CITY:			PROVIDENCIALES, GRACE BAY
		STATE:			W7
		ZIP:			TKCAZZI
</SEC-HEADER>
<DOCUMENT>
<TYPE>SCHEDULE 13G
<SEQUENCE>1
<FILENAME>primary_doc.xml
<TEXT>
<XML>
<?xml version="1.0" encoding="UTF-8"?><edgarSubmission xmlns="http://www.sec.gov/edgar/schedule13g" xmlns:com="http://www.sec.gov/edgar/common">
  <headerData>
    <submissionType>SCHEDULE 13G</submissionType>
    <filerInfo>
      <filer>
        <filerCredentials>
          <!-- Field: Pseudo-Tag; ID: Name; Data: GREENFIELD INVESTMENTS LTD. -->
          <cik>0002052615</cik>
          <ccc>XXXXXXXX</ccc>
        </filerCredentials>
      </filer>
      <liveTestFlag>LIVE</liveTestFlag>


    </filerInfo>
  </headerData>
  <formData>
    <coverPageHeader>
      <securitiesClassTitle>Common Stock, par value $0.001 per share</securitiesClassTitle>
      <eventDateRequiresFilingThisStatement>12/13/2024</eventDateRequiresFilingThisStatement>
      <issuerInfo>
        <issuerCik>0001938046</issuerCik>
        <issuerName>Mangoceuticals, Inc.</issuerName>
        <issuerCusip>56270V205</issuerCusip>
        <issuerPrincipalExecutiveOfficeAddress>
          <com:street1>15110 Dallas Parkway,</com:street1>
          <com:street2>Suite 600,</com:street2>
          <com:city>Dallas,</com:city>
          <com:stateOrCountry>TX</com:stateOrCountry>
          <com:zipCode>75248</com:zipCode>
        </issuerPrincipalExecutiveOfficeAddress>
      </issuerInfo>
      <designateRulesPursuantThisScheduleFiled>
        <designateRulePursuantThisScheduleFiled>Rule 13d-1(c)</designateRulePursuantThisScheduleFiled>
      </designateRulesPursuantThisScheduleFiled>
    </coverPageHeader>
    <coverPageHeaderReportingPersonDetails>


      <reportingPersonName>Greenfield Investments, Ltd</reportingPersonName>
      <citizenshipOrOrganization>W7</citizenshipOrOrganization>
      <reportingPersonBeneficiallyOwnedNumberOfShares>
        <soleVotingPower>0.00</soleVotingPower>
        <sharedVotingPower>515000.00</sharedVotingPower>
        <soleDispositivePower>0.00</soleDispositivePower>
        <sharedDispositivePower>515000.00</sharedDispositivePower>
      </reportingPersonBeneficiallyOwnedNumberOfShares>
      <reportingPersonBeneficiallyOwnedAggregateNumberOfShares>515000.00</reportingPersonBeneficiallyOwnedAggregateNumberOfShares>
      <aggregateAmountExcludesCertainSharesFlag>N</aggregateAmountExcludesCertainSharesFlag>
      <classPercent>14.44</classPercent>
      <typeOfReportingPerson>PN</typeOfReportingPerson>
    </coverPageHeaderReportingPersonDetails>
    <coverPageHeaderReportingPersonDetails>

      <reportingPersonName>Peter M. Karam</reportingPersonName>
      <citizenshipOrOrganization>A8</citizenshipOrOrganization>
      <reportingPersonBeneficiallyOwnedNumberOfShares>
        <soleVotingPower>0.00</soleVotingPower>
        <sharedVotingPower>515000.00</sharedVotingPower>
        <soleDispositivePower>0.00</soleDispositivePower>
        <sharedDispositivePower>515000.00</sharedDispositivePower>
      </reportingPersonBeneficiallyOwnedNumberOfShares>
      <reportingPersonBeneficiallyOwnedAggregateNumberOfShares>515000.00</reportingPersonBeneficiallyOwnedAggregateNumberOfShares>
      <aggregateAmountExcludesCertainSharesFlag>N</aggregateAmountExcludesCertainSharesFlag>
      <classPercent>14.44</classPercent>
      <typeOfReportingPerson>IN</typeOfReportingPerson>
    </coverPageHeaderReportingPersonDetails>
    <items>
      <item1>
        <issuerName>Mangoceuticals, Inc.</issuerName>
        <issuerPrincipalExecutiveOfficeAddress>15110 Dallas Parkway, Suite 600, Dallas, TX 75248</issuerPrincipalExecutiveOfficeAddress>
      </item1>
      <item2>
        <filingPersonName>(i) Greenfield Investments, Ltd

(ii) Peter M. Karam</filingPersonName>
        <principalBusinessOfficeOrResidenceAddress>(i) Suites A201&amp; A202 (Upstairs), Regent Village East, Grace Bay, Providenciales, Turks and Caicos Islands

(ii) P.O. Box 926, Suite A203 &amp; 204, Regent Village East Grace Bay, Providenciales, Turks and Caicos Islands</principalBusinessOfficeOrResidenceAddress>
        <citizenship>(i) Turks and Caicos

(ii) Canadian</citizenship>
      </item2>
      <item3>
        <notApplicableFlag>Y</notApplicableFlag>
      </item3>
      <item4>
        <amountBeneficiallyOwned>515,000.00</amountBeneficiallyOwned>
        <classPercent>14.44</classPercent>
        <numberOfSharesPersonHas>
          <solePowerOrDirectToVote>0.00</solePowerOrDirectToVote>
          <sharedPowerOrDirectToVote>515,000.00</sharedPowerOrDirectToVote>
          <solePowerOrDirectToDispose>0.00</solePowerOrDirectToDispose>
          <sharedPowerOrDirectToDispose>515,000.00</sharedPowerOrDirectToDispose>
        </numberOfSharesPersonHas>
      </item4>
      <item5>
        <notApplicableFlag>Y</notApplicableFlag>
      </item5>
      <item6>
        <notApplicableFlag>Y</notApplicableFlag>
      </item6>
      <item7>
        <notApplicableFlag>Y</notApplicableFlag>
      </item7>
      <item8>
        <notApplicableFlag>Y</notApplicableFlag>
      </item8>
      <item9>
        <notApplicableFlag>Y</notApplicableFlag>
      </item9>
      <item10>
        <notApplicableFlag>N</notApplicableFlag>
        <certifications>By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.</certifications>
      </item10>
    </items>
    <exhibitInfo>Item 4: Information with respect to the Reporting Persons' ownership of the Common Stock as of January 22, 2025, is incorporated by reference to items (5) - (9) and (11) of the cover page of the respective Reporting Person. The amount beneficially owned by each Reporting Person is determined using 3,565,641 shares of the Issuer outstanding as of January 22, 2025, as confirmed by the Issuer's transfer agent on such date.

JOINT FILING STATEMENT

PURSUANT TO RULE 13d-1(k)

The undersigned acknowledge and agree that the foregoing statement on SCHEDULE 13G, is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on SCHEDULE 13G, shall be filed on behalf of each of the undersigned without the necessity of filing additional joint acquisition statements. The undersigned acknowledge that each shall be responsible for the timely filing of such amendments, and for the completeness and accuracy of the information concerning him or it contained therein, but shall not be responsible for the completeness and accuracy of the information concerning the others, except to the extent that he or it knows or has reason to believe that such information is inaccurate.

Dated: January 22, 2025

Greenfield Investments, Ltd

By: /s/ Peter M. Karam,  Peter M. Karam Director

By: /s/ Peter M. Karam Peter M. Karam</exhibitInfo>
    <signatureInformation>
      <reportingPersonName>Greenfield Investments, Ltd</reportingPersonName>
      <signatureDetails>
        <signature>/s/ Peter M. Karam</signature>
        <title>Peter M. Karam</title>
        <date>01/21/2025</date>
      </signatureDetails>
    </signatureInformation>
    <signatureInformation>
      <reportingPersonName>Peter M. Karam</reportingPersonName>
      <signatureDetails>
        <signature>/s/ Peter M. Karam</signature>
        <title>Peter M. Karam</title>
        <date>01/22/2025</date>
      </signatureDetails>
    </signatureInformation>
  </formData>
</edgarSubmission>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
